ArticleCell death discovery2018
Effects of tumor treating fields (TTFields) on glioblastoma cells are augmented by mitotic checkpoint inhibition.
Article in Cell death discovery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 43 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 3 syntheses or guidelines pooled it, 61 citations in OpenAlex.
- Impact of tumor treating fields on overall and progression-free survival in newly diagnosed glioblastoma: A systematic review and meta-analysis.Neurosurgical review · 2026Pooled it
- Association of Tumor Treating Fields (TTFields) therapy with survival in newly diagnosed glioblastoma: a systematic review and meta-analysis.Journal of neuro-oncology · 2023Pooled it
- Efficacy and safety of tumor-treating fields in recurrent glioblastoma: a systematic review and meta-analysis.Acta neurochirurgica · 2022Pooled it
- MAGMAS Inhibition Enhances Temozolomide Efficacy in Chemotherapy-Resistant Glioblastoma Models.Cancer research communications · 2026Article
- Selective antitumor activity of Tumor Treating Fields (TTFields) involving molecular factors in cancer cells and tumor microenvironment.Translational oncology · 2025Review
- The therapeutic efficacy and application prospects of tumor-treating fields (TTFields) in resolving malignant tumors of central nervous system.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Review
- An Analysis for IDH-Mutant Grade 4 Astrocytoma Based on WHO CNS 5: Implication of Clinical Practice.Annals of clinical and translational neurology · 2025Article
- Advancement in tumor treating fields of mechanism, clinical applications, and future directions.Discover oncology · 2025Review
- Tumor-treating fields in cancer therapy: advances of cellular and molecular mechanisms.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Review
- Tumor-treating fields and concurrent cisplatin: anAmerican journal of cancer research · 2025Article
- Electrodynamic interaction between tumor treating fields and microtubule electrophysiological activities.APL bioengineering · 2024Article
- Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives.Journal of hematology & oncology · 2024Review
- Advanced tumor electric fields therapy: A review of innovative research and development and prospect of application in glioblastoma.CNS neuroscience & therapeutics · 2024Review
- Theory and application of TTFields in newly diagnosed glioblastoma.CNS neuroscience & therapeutics · 2024Review
- A review of tumor treating fields (TTFields): advancements in clinical applications and mechanistic insights.Radiology and oncology · 2023Review
- Optimization of tumor-treating field therapy for triple-negative breast cancer cells in vitro via frequency modulation.Cancer cell international · 2023Article
- Therapeutic potential of tumor treating fields for malignant brain tumors.Cancer reports (Hoboken, N.J.) · 2023Review
- Anti-cancer mechanisms of action of therapeutic alternating electric fields (tumor treating fields [TTFields]).Journal of molecular cell biology · 2022Review
- Glioblastoma-Derived Three-Dimensional Ex Vivo Models to Evaluate Effects and Efficacy of Tumor Treating Fields (TTFields).Cancers · 2022Article
- The Mechanisms of Action of Tumor Treating Fields.Cancer research · 2022Review
Corrections and comments
- Erratum issued
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor treating fields (TTFields) are approved for glioblastoma (GBM) therapy. TTFields disrupt cell division by inhibiting spindle fiber formation. Spindle assembly checkpoint (SAC) inhibition combined with antimitotic drugs synergistically decreases glioma cell growth in cell culture and mice. We hypothesized that SAC inhibition will increase TTFields efficacy. Human GBM cells (U-87 MG, GaMG) were treated with TTFields (200 kHz, 1.7 V/cm) and/or the SAC inhibitor MPS1-IN-3 (IN-3, 4 µM). Cells were counted after 24, 48, and 72 h of treatment and at 24 and 72 h after end of treatment (EOT). Flow cytometry, immunofluorescence microscopy, Annexin-V staining and TUNEL assay were used to detect alterations in cell cycle and apoptosis after 72 h of treatment. The TTFields/IN-3 combination decreased cell proliferation after 72 h compared to either treatment alone (-78.6% vs. TTFields,
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.